CA3145973A1 - Hpk1 inhibitors and uses thereof - Google Patents

Hpk1 inhibitors and uses thereof Download PDF

Info

Publication number
CA3145973A1
CA3145973A1 CA3145973A CA3145973A CA3145973A1 CA 3145973 A1 CA3145973 A1 CA 3145973A1 CA 3145973 A CA3145973 A CA 3145973A CA 3145973 A CA3145973 A CA 3145973A CA 3145973 A1 CA3145973 A1 CA 3145973A1
Authority
CA
Canada
Prior art keywords
alkyl
alkoxy
halogen
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3145973A
Other languages
English (en)
French (fr)
Inventor
Wenge Zhong
Xiaotian Zhu
Song Feng
Lei Wu
Wei Huang
Hao Liu
Rongqiang LIU
Kate Xin Wen
Hua Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regor Pharmaceuticals Inc
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74100919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3145973(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of CA3145973A1 publication Critical patent/CA3145973A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3145973A 2019-07-04 2020-07-03 Hpk1 inhibitors and uses thereof Pending CA3145973A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/094634 2019-07-04
CN2019094634 2019-07-04
PCT/CN2020/100134 WO2021000935A1 (en) 2019-07-04 2020-07-03 Hpk1 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA3145973A1 true CA3145973A1 (en) 2021-01-07

Family

ID=74100919

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3145973A Pending CA3145973A1 (en) 2019-07-04 2020-07-03 Hpk1 inhibitors and uses thereof

Country Status (16)

Country Link
US (2) US12612424B2 (cg-RX-API-DMAC7.html)
EP (2) EP3994133A4 (cg-RX-API-DMAC7.html)
JP (2) JP7633989B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220044495A (cg-RX-API-DMAC7.html)
CN (2) CN114555585B (cg-RX-API-DMAC7.html)
AU (2) AU2020298649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000064A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145973A1 (cg-RX-API-DMAC7.html)
DK (1) DK4175951T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981368T3 (cg-RX-API-DMAC7.html)
FI (1) FI4175951T3 (cg-RX-API-DMAC7.html)
IL (1) IL289612B2 (cg-RX-API-DMAC7.html)
MA (1) MA56462A (cg-RX-API-DMAC7.html)
MX (2) MX2022000271A (cg-RX-API-DMAC7.html)
TW (1) TWI878319B (cg-RX-API-DMAC7.html)
WO (2) WO2021000935A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2021000935A1 (en) 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
CN116456985A (zh) * 2020-09-23 2023-07-18 深圳市原力生命科学有限公司 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法
US20230399327A1 (en) * 2020-10-28 2023-12-14 Adlai Nortye Biopharma Co., Ltd. High activity hpk1 kinase inhibitor
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117295737A (zh) * 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN117295748A (zh) * 2021-03-08 2023-12-26 缆图药品公司 Map4k1抑制剂
JP2024510176A (ja) * 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Map4k1阻害剤
TW202246263A (zh) * 2021-03-23 2022-12-01 大陸商杭州阿諾生物醫藥科技有限公司 Hpk1激酶抑制劑化合物
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117377673A (zh) * 2021-03-29 2024-01-09 林伯士萨顿公司 Hpk1拮抗剂和其用途
TW202304906A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 高活性hpk1激酶抑制劑
MX2024000751A (es) * 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
EP4377318A4 (en) * 2021-07-30 2025-06-04 BeiGene, Ltd. PYRROLO[2,3-B PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND USE THEREOF
WO2023083299A1 (zh) * 2021-11-12 2023-05-19 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023134608A1 (zh) * 2022-01-11 2023-07-20 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023245329A1 (en) * 2022-06-20 2023-12-28 Biofront Ltd Multi-kinase inhibitors, compositions thereof, and methods of using the same
CN117447470B (zh) * 2023-02-20 2026-05-01 杭州医学院 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用
CN116813692A (zh) * 2023-06-29 2023-09-29 凌科药业(杭州)有限公司 含磷化合物、其药物组合物及其用途
WO2025096647A1 (en) * 2023-10-30 2025-05-08 Nimbus Saturn, Inc. Methods of treating tumors
WO2025137168A2 (en) 2023-12-19 2025-06-26 Regor Pharmaceuticals, Inc. Salt and solid forms of a hpk1 inhibitor
WO2025255343A1 (en) * 2024-06-06 2025-12-11 Dana-Farber Cancer Institute, Inc. Pyrrolopyrimidine inhibitors of wild-type and mutant lrrk2

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
WO2008003766A2 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
CA2673003A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
WO2008110508A1 (en) 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. 2-アミノキナゾリン誘導体
US20100121052A1 (en) 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
EP2248907A1 (en) 2009-05-08 2010-11-10 Rijksuniversiteit Groningen Gluco-oligosaccharides comprising (alpha 1-->4) and (alpha 1-->6) glycosidic bonds, use thereof, and methods for providing them
WO2012135631A1 (en) * 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
US9708336B2 (en) 2014-01-22 2017-07-18 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CN106188029B (zh) * 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
ES2921257T3 (es) 2016-06-20 2022-08-22 Daegu Gyeongbuk Medical Innovation Found Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
EP3596075B1 (en) 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles as inhibitors of hpk1
US20200071326A1 (en) 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
WO2018215668A1 (en) 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN109721620B (zh) 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020235902A1 (ko) 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
WO2021000935A1 (en) 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof

Also Published As

Publication number Publication date
MX2022000271A (es) 2022-04-20
WO2022002237A1 (en) 2022-01-06
CN114555585A (zh) 2022-05-27
US20230339896A1 (en) 2023-10-26
MA56462A (fr) 2022-05-11
BR112022000064A2 (pt) 2022-05-24
TW202116751A (zh) 2021-05-01
AU2021299849A1 (en) 2023-02-23
CN116096370A (zh) 2023-05-09
AU2020298649B2 (en) 2026-04-09
EP3994133A4 (en) 2023-11-22
KR20220044495A (ko) 2022-04-08
MX2023000025A (es) 2023-04-04
IL289612B2 (en) 2026-02-01
CN116096370B (zh) 2024-12-20
KR20230035061A (ko) 2023-03-10
WO2021000935A1 (en) 2021-01-07
DK4175951T3 (da) 2024-07-29
US12612424B2 (en) 2026-04-28
AU2020298649A1 (en) 2022-02-17
JP7759374B2 (ja) 2025-10-23
TWI878319B (zh) 2025-04-01
US12617811B2 (en) 2026-05-05
EP4175951B1 (en) 2024-05-01
FI4175951T3 (fi) 2024-07-10
EP3994133A1 (en) 2022-05-11
JP7633989B2 (ja) 2025-02-20
ES2981368T3 (es) 2024-10-08
IL289612B1 (en) 2025-10-01
EP4175951A1 (en) 2023-05-10
JP2022538923A (ja) 2022-09-06
US20220389037A1 (en) 2022-12-08
JP2023533938A (ja) 2023-08-07
CN114555585B (zh) 2025-02-11
IL289612A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
AU2020298649B2 (en) HPK1 inhibitors and uses thereof
US11492354B2 (en) Indazole compounds and uses thereof
US11242343B2 (en) Pyrazolopyridine compounds and uses thereof
TWI828653B (zh) 甲醯胺化合物及其用途
JP7118267B2 (ja) がんの処置のためのHPK1阻害剤としての2,3-ジヒドロ-1H-ピロロ[3,4-c]ピリジン-1-オン誘導体
TWI828027B (zh) 作為tam抑制劑之吡咯并三嗪化合物
DK2376478T3 (en) Pyridyloxyindoline inhibitors for VEGF-R2 and its use in the treatment of diseases
KR20170066566A (ko) Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도
JP2020514272A (ja) 免疫調節剤としての二環式複素芳香環化合物
WO2021233236A1 (zh) 取代的杂芳基化合物及其组合物和用途
TW202509014A (zh) GSK3α抑制劑及其使用方法
RU2839132C2 (ru) Ингибиторы hpk1 и их применение
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a
HK40090215A (en) Hpk1 inhibitors and uses thereof
TW201938560A (zh) 稠環雙環吡啶基衍生物
HK1171742A (en) Tricyclic pyrazol amine derivatives

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240702

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241021

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241107

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241107

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250710

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260114

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260114

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260626

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260626